INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Increased survival of patients with cystic fibrosis has focused attention on quality of life, alongside longevity1

Adults with CF have complex infections2 – at least 170 different bacteria have been identified to comprise the microbiome of an adult with CF.2

As they get older, the respiratory microbiome of a person with CF changes.3,4

REPORTED LUNG INFECTIONS IN UK CF PATIENTS IN 20175

Adapted from Cystic Fibrosis Registry, 2017 Annual Data Report5

Pseudomonas aeruginosa is a common chronic infection, affecting up to 80% of adults with CF.4,6,7

Bramitob® (tobramycin) is for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis aged 6 years or older.8


1. Royce FH and Carl JC, Curr Opin Pediatr. 2011;23(5)535-40.
2. Price KE, et al. Microbiome. 2013;1-27.
3. Filkins L, et al. Plos Pathog. 2015;11(12):1-8.
4. Coburn B,et al. Sci Rep. 2015;5:10241. Doi:10.1038/prep10241.
5. UK Cystic Fibrosis Registry. Annual Data Report 2017. Cystic Fibrosis Trust.
6. LiPuma J. J Clin Micro Rev. 2010;23:299-23.
7. Smyth AR, et al. J Cyst Fibros. 2014;13:523-42.
8. Bramitob® Summary of Product Characteristics. Available online at https://www.medicines.org.uk/emc/medicine/21427. Accessed September 2018.